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Enquadramento: Apesar dos avanços na área da transplantação de células progenitoras 
hematopoiéticas, o transplante alogénico continua a associar-se a importantes 
complicações, com elevada morbi-mortalidade, como a doença de enxerto-contra-
hospedeiro crónica e neoplasias secundárias. A doença de enxerto-contra-hospedeiro 
crónica e o seu tratamento foram identificados como potenciais factores de risco para o 
desenvolvimento de neoplasias secundárias após transplante, nomeadamente neoplasias 
sólidas. No entanto existem poucos estudos que analisem o papel da doença de enxerto-
contra-hospedeiro crónica no risco de neoplasias secundárias. 
Objectivo: Analisar e clarificar o papel da doença de enxerto-contra-hospedeiro crónica 
e do tratamento imunosupressor associado, no desenvolvimento de neoplasias 
secundárias após transplante alogénico de células progenitoras hematopoieticas. Como 
objectivo final, este trabalho pretende aumentar a sensibilização para esta complicação 
tardia, no seguimento a longo-prazo destes doentes.  
Método: Revisão sistemática da literatura, através da pesquisa na base de dados 
Pubmed, com inclusão final de 29 artigos científicos.  
Resultados: A doença de enxerto-contra-hospedeiro crónica parece ser um factor de 
risco independente para neoplasias sólidas, nomeadamente para carcinomas pavimento-
celulares de regiões frequentemente afectadas pela doença, como a cavidade oral, pele 
e, nalgumas populações, o esófago. O risco de neoplasia sólida parece aumentar com a 
duração do tratamento imunosupressor, quando este é superior a 24 meses, e com o uso 
de azatioprina. A associação da doença de enxerto-contra-hospedeiro crónica com 
outros tipos de neoplasias secundárias foi inconclusiva. 
Conclusão: Os doentes com doença de enxerto-contra-hospedeiro crónica parecem ter 
um risco aumentado para neoplasias secundárias, nomeadamente neoplasias sólidas. 
Estas neoplasias tendem a surgir tardiamente, o que sugere um benefício na instituição 
de rotinas de rastreio oncológico a longo-termo, sobretudo para neoplasias da pele, 
cavidade oral, e nalgumas populações, esófago. 
Palavras-Chave: Segundas neoplasias, doença de enxerto-contra-hospedeiro crónica, 
transplante alogénico de células progenitoras hematopoiéticas, neoplasias sólidas. 




Background: Despite the advances in hematopoietic stem cell transplantation, allogeneic 
transplants are still associated with significant morbidity and mortality, due to late 
complications, such as chronic graft-versus-host disease and secondary malignancies. 
Both chronic graft-versus-host disease and its treatment have been implied as potential 
risk factors for secondary malignancies in patients undergoing allogeneic hematopoietic 
stem cell transplant, particularly for solid tumors. However the literature on the role of 
chronic graft-versus-host disease on the development of secondary malignancy is 
scarce.   
Goals: Analyze and clarify the role of chronic graft-versus-host disease, and its 
immunosuppressive treatment, on the development of secondary malignancies after 
allogeneic stem cell transplantation. The final goal is to increase awareness for this late 
complication in the long-term follow up of these patients.  
Methods: This is a systematic literature review, covering 29 articles, after a thorough 
search in Pubmed database. 
Results: Chronic graft-versus-host disease seems to be an independent risk factor for 
solid tumors, namely for squamous cell carcinomas of regions frequently affected by the 
disease, such as the oral cavity, skin and, in some populations, the esophagus. The risk 
for solid tumors seems to increase with treatment duration, when surpassing 24 months, 
and with the use of azathioprine. The association between chronic graft-versus-host 
disease and other secondary malignancies was inconclusive.  
Conclusions: Patients with chronic graft-versus-host disease seem to have an increased 
risk for secondary malignancies, namely solid tumors. Solid tumors tend to occur later 
in the follow-up, suggesting a benefit in cancer screening guidelines for the long-term-
survivors, particularly for skin, oral cavity, and esophagus cancer. 
Key-Words: Secondary malignancies, chronic graft-versus-host disease, allogeneic 
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Hematopoietic stem cell transplantation (HSCT) is the standard of care for many 
hematologic malignancies, and some congenital or acquired disorders of the 
hematopoietic system(1). Since the first transplant procedure, 50 years ago, HSCT 
utilization expanded all over the world, being effectively applied in solid tumors, 
congenital immunodeficiency disorders, and hereditary metabolic diseases(1). 
The dramatic increase in the number of HSCT, namely allogeneic transplants (allo-
HSCT), was possible due to the expansion to unrelated and alternative donors and the 
development of reduced intensity-conditioning regimes. These procedures, together 
with advances in the post-transplant supportive care have led to a decline in transplant-
related mortality (TRM), and consequently an increase in the number of long-term 
survivors(2). Despite this improvement, allo-HSCT is still associated with an important 
morbidity and long-term mortality, with fifteen-year survivors having mortality rates at 
least twice as high as the general population(3). 
According to the literature, the leading causes of mortality after transplant are secondary 
malignancies, disease relapse, infections, chronic graft-versus-host disease (cGVHD) 
and respiratory and cardiovascular diseases(4). 
Focusing on secondary malignancies, these include lymphoproliferative diseases 
(PTLD), secondary leukemia, and solid tumors. Both cGVHD and its treatment have 
been reported as potential risk factors for the development of certain types of secondary 
malignancies, namely solid tumors(5–8); however there is still no consensus regarding 
the mechanisms through which cGVHD can increase this risk. 
The main purpose of this review is to analyze and clarify the suggested role of cGVHD 
in the development of secondary malignancies, with the ultimate goal of increasing the 
awareness of this complication in the long-term follow-up of patients undergoing allo-
HSCT. Furthermore, we aim to evaluate the impact of the type and duration of 
immunosuppressive treatment (IS) for cGVHD in the development of secondary 
malignancies.  
As such we begin by providing an overview of cGVHD and the plausible mechanisms 
responsible for the suggested association between cGVHD and secondary malignancies. 
We then proceed with a systematic review of the literature, aiming to find evidence 
regarding this association.   
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Chronic Graft-versus-Host Disease - Overview 
cGVHD is a major late complication of allo-HSCT, affecting 30 to 70% of transplanted 
patients(9,10). Its prevalence has been increasing, possibly due to factors such as the 
increasing age of recipients, use of unrelated-donors and peripheral-blood progenitor 
cells, and the advances in supportive care, which increase long-term HSCT survival 
rates(11). 
cGVHD is a multisystem disorder with features of auto-immunity, that stems from the 
interaction between the donor’s and the host’s immune system. Despite the complex 
pathophysiology of cGVHD, studies consistently show an immune-deregulation of 
several populations of T and B-cells and an abnormal production of cytokines and 
chemokines, which contribute to the amplification of the inflammatory response and 
tissue damage. The resulting chronic immune-dysfunction and the subsequent long-term 
IS contribute to significant mortality (12).  
Both infused donor T-cells and engrafting donor T-cells seem to have a role in the 
development of cGVHD. The studies suggesting a role for the infused donor T-cells 
show a lower incidence of cGVHD in T-cell depleted grafts and after anti-thymocyte 
globulin (ATG) therapy(13). The studies suggesting a role for the engrafting donor T-
cells show an imbalance between CD4+ regulatory T-cells (Treg), which are decreased, 
and effector cells such as CD4+ conventional T-cells and CD8+ cells, that mediate the 
disease directly or through the production of inflammatory cytokines.  
Within the B-cell compartment, studies have shown an increase in BAFF levels, and a 
subsequent increase in B-cells’ half-life with further differentiation into plasma cells. 
These latter will generate auto and allo-antibodies, which seem to correlate with the 
onset and severity of cGVHD(9).  
The presentation of cGVHD is variable, there being cases of single organ involvement 
and cases affecting several sites, including the skin, oral mucosa, digestive tract, liver 
and eyes. Certain manifestations are considered diagnostic, such as poikiloderma; 
lichen-like lesions of the skin, genitals and oral cavity; skin sclerosis; superior 
esophageal stenosis; esophageal webbing; bronchiolitis obliterans and connective tissue 
alterations (fasciitis, sclerosis and articular stiffness/contracture). Frequently cGVHD 
displays distinctive manifestations, which are suggestive but not diagnostic; these 
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correspond to autoimmune features such as malar rash, sicca syndrome, arthritis or 
cholestasis. The diagnosis of cGVHD requires the presence of one diagnostic 
manifestation or at least one distinctive clinical sign confirmed by biopsy or other 
relevant tests.  
Typically the disease presents within the first year post-transplant, although it can 
appear later on. Occasionally it is preceded by acute GVHD (aGVHD).   
Formerly the classification of acute or chronic GVHD was exclusively based on the 
time of onset, with cGVHD occurring more than 100 days post-transplant. However, in 
2005 the NIH GVHD Consensus Response Criteria Working Group created criteria for 
a standardized diagnosis based on clinical features(14). Apart from the classic aGVHD 
there is a late form with characteristics of aGVHD that presents/persists after 100 days; 
besides the classic cGVHD there is the so-called overlap syndrome, defined by the 
coexistence of aGVHD and cGVHD features. This working group also proposed a 
scoring system for organ-specific (0-3) and global (mild, moderate, severe) severity, 
replacing the classic “limited” and “extensive” classifications. These modifications were 
maintained after a subsequent review in 2014, which addresses controversies as overlap 
syndrome and active disease versus past tissue damage(10).  
The complex biology of cGVHD justifies the lack of available successful strategies to 
prevent and treat this disease. While for  the prevention of aGVHD there is an immune- 
suppressive regimen that is started soon after transplant to control the infused donor T-
cell activation, usually combining methotrexate with a calcineurin inhibitor 
(cyclosporine/tacrolimus)(15), for cGVHD there are few successful strategies. The use 
of marrow harvested stem cells instead of peripheral blood stem cells (PBSC)(16), and 
the in-vivo T-cell depletion with ATG, in the conditioning regimen, seem to decrease 
the incidence of cGVHD(17,18). 
Regarding the treatment of cGVHD, the available options suppress the inflammatory 
response, being efficacious in managing many of the clinical manifestations(15). The 
first line treatment for cGVHD is corticosteroids in combination with a calcineurin 
inhibitor, such as cyclosporine or tacrolimus. Although this dual treatment allows the 
use of a lower steroid dose, and a lower induced toxicity, it did not demonstrate any 
benefit on the mortality rate(19,20). Systemic treatment, lasting at least 1 year, is 
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recommended for patients with moderate to severe disease(21); mild disease can often 
be treated topically, with efficacy. 
However, 50% of patients fail to respond to the frontline treatment. We consider failure 
when there is clinical progression under high doses of prednisone (1mg/Kg/d) for at 
least 2 weeks, clinical stability only under high doses of prednisone (>0.5mg/Kg/d) for 
1-2 months, or when it’s not possible to taper prednisone to lower doses (<0.5 
mg/kg/d)(22). So far there is no established second-line treatment for refractory cGVHD 
patients, as such it is recommended, if possible, to enroll these patients in clinical trials. 
Available second-line drugs include(21,23): 
• immune suppressive nonspecific agents, that spare Tregs, such as: m-TOR 
inhibitors (sirolimus), pentostatin for skin involvement, and Mycophenolate 
mofetil (MMF);  
• monoclonal antibodies, that cause B cell depletion, such as rituximab; 
• specific pathway inhibitors, such as: ibrutinib (recently approved), imatinib, 
ruxolitinib; NF-kb and proteasome inhibitor bortezomib; 
• immune regulatory treatments, which induce tolerance by inducing Treg 
expansion, such as extracorporeal photophoresis for skin or oral cGVHD, IL-2, 
therapy and Treg infusion.  
Besides these approaches, cGVHD patients should receive supportive treatment, which 
may include analgesics, infectious prophylaxis, eye drops for dryness, among others.  
Available studies suggest that the chronic inflammation and immune dysregulation of 
cGVHD may cause malignant transformation. The impact of cGVHD and/or it’s IS 
treatment on the development of secondary malignancies remains uncertain. However, it 
is possible that the disease’s inflammatory context combined with the chronic 
immunosuppression contribute to failures in immune surveillance/vigilance and failures 
in tissue repair mechanisms, increasing the risk for tumoral evolution (24–26).  
Secondary Malignancies after HSCT – Overview 
Secondary malignancies are a known complication in long-term allo-HSCT survivors. A 
population-based Australian cohort (≥15 years follow-up) of 3273 allo-HSCT patients 
reported a cumulative incidence of secondary malignancies of 3.35% at 10 years, with 
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transplant recipients having at least twice the risk of secondary malignancies compared 
to the general population(5). 
These malignancies can be grouped into three categories, which are: donor-type 
secondary leukemia (AML)/myelodysplastic syndrome (MDS), post-transplant 
lymphoproliferative disorders (PTLD), and solid tumors. While the first two tend to 
develop in the first 10 years post-transplant, the incidence of solid tumors continues to 
increase even 20 years after transplant(27). A study of 2150 allo-HSCT recipients 
showed that the cumulative incidence of secondary malignancies was 9.9% at 10 years, 
with PTLD plateauing at 4 years (1.6%), AML/MDS plateauing at 9 years (2.1%), and 
solid tumors increasing continuously, even after 13 years (5.6%)(6). 
Focusing on solid malignancies, Rizzo studied 28874 allo-HSCT recipients and reported 
an incidence of solid cancer around twice the reported in the general population, 
reaching cumulative incidences of 2.5%, 5.8% and 8.8%, at 10, 15 and 20 years, 
respectively, with increased risk for cancers of the oral cavity, skin, liver, central 
nervous system, thyroid, bone, soft tissues, and melanoma(28). This distribution was 
confirmed by another study, reporting cumulative incidences of solid cancer of 0.7%, 
2.2% and 6.7%, at 5, 10 and 15 years, respectively(29).  
Many factors have been suggested to increase the risk for solid cancer after allo-HSCT, 
such as age at the time of transplant, with elderly patients having an increased risk due 
to age-related risk; pre-transplant treatment or conditioning regimen, with an increased 
mutagenic risk associated to irradiation; cGVHD and prolonged immunosuppression.  
Chronic GVHD seems to be an independent risk factor for all solid cancers, namely for 










This systematic review of the literature includes articles that report the incidence and 
risk for secondary malignancies after allo-HSCT, and consider GVHD amongst their 
variables.   
The research question and the eligibility criteria were defined using the PICOD method: 
• P (participants): recipients of allo-HSCT. 
• I (intervention): patients with cGVHD. 
• C (comparison): allo-HSCT recipients without cGVHD. 
• O (outcomes):  
o primary outcome: secondary malignancies;  
o secondary outcomes: type of malignancy, immunosuppressive drug(s) 
(IS) utilized, duration of IS.. 
• D (design): systematic review including retrospective cohort and case-control 
studies. 
This study was performed respecting the different phases recommended by PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses), and 
represented in Figure 1: 
1. Identification/Information sourcing: we used the PubMed database 
searching, with combinations of the following keywords: Second Cancers, 
GVHD, HSCT, Solid Cancers, PTLD. This resulted in 1054 results 
2. Screening: in this phase we excluded review articles, case-reports and 
studies not concerning allo-HSCT (n=1029). As such only 25 articles were 
selected for eligibility.  
3. Eligibility: Title and abstract selection excluded 3 studies where cGVHD 
was not a risk variable; 22 articles remained for full-test reading.  
4. Included: After screening the references of the eligible articles, we added 13 






















































Studies identified by database 
search (n=1054) 
Studies selected based on title and 
abstract (n= 25) 
Excluded studies (n=1029): 
- Review articles 
- Case-reports 
- Studies without allogeneic 
transplant recipients.   
 
Excluded studies (n=3): 
- Studies where cGVHD wasn’t 
studied as a risk variable.  
 
Studies selected after full-text 
analysis (n= 22) 
Excluded studies (n=6): 
- Review articles  
- Case-reports 
 
Studies selected in total (n= 29) 
Additional studies selected from 
reference lists (n= 13) 
Studies selected after full-text 
analysis (n= 7) 
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Results and Discussion  
This review includes a total of 29 articles published between 1996 and 2017 (period of 
20 years). The characteristics of the studies can be consulted in supplementary Table 1. 
Of the total 29 articles analyzed, 28 referred to retrospective cohort studies and 1 was a 
case-control study. These were conducted in different geographical locations, allowing 
for the collection of data from all five continents.  
The studies were heterogeneous when it came to sample size, ranging from 38 to 68936 
patients, with a median age at HSCT of 32 years (10-55 years). 21 studies included 
exclusively allo-HSCT recipients, of these 13 stated the source of progenitor stem cells, 
which were blood marrow, peripheral blood and cord blood in 88%, 9% and 3% of 
patients, respectively.  
The incidence of cGVHD was stated in 22 studies, ranging from 10% to 97%, with an 
average incidence of 41%. The majority of studies didn’t state the type of IS used; those 
that mentioned, mainly used corticosteroids, cyclosporine, azathioprine, MMF, ATG 
and tacrolimus. Only 1 study stated the duration of IS, with 24.7% doing more than 1 
year.  
Of the listed studies, 16 clearly stated the average time between HSCT and the 
development of secondary malignancies, with an average of 6,55 years (3,54-7,6 years) 
for all type secondary malignancies, 0,75 years for PTLD, 7 years for all-type secondary 
solid tumors (ST) (5,6-10 years) and 8,6 years (8,5-8,7 years) for thyroid cancer.  
Impact of cGVHD on the development of secondary malignancies 
From the 29 studies included in this analysis, 19 reported a statistically significant 
association between cGVHD and secondary malignancies, specifically ST, 
hematological malignancies or both.  
Regarding the impact of cGVHD on secondary malignancies of all-type, this was only 
accessed in 3 studies(5).  In Vajdic’ study cGVHD patients had an increased incidence 
of secondary malignancies compared to the general population (SIR 1.51-2.82). The 
studies from Shimada and Abou-Mourad failed to demonstrate cGVHD as a risk factor 
for secondary malignancies; however in Shimada´s study 14 of the 16 cancer cases 
(BCCs or SCCs of the skin and oral cavity) were diagnosed in cGVHD patients 





cGVHD impact on Solid Tumors  
From the 29 studies analyzed, 23 assessed the impact of cGVHD on the risk for 
secondary ST. On average ST were diagnosed between 1 to 10 years after allo-HSCT, 
with most cases appearing within a 5 to 8 year range.  
Two studies focused on secondary thyroid cancers, with only one showing a significant 
correlation to cGVHD. In a study including 68936 HSCT recipients, 32 thyroid cancers 
were diagnosed, with cGVHD appearing as a significant risk factor(33). In a smaller 
study cGVHD failed to attain statistical significance as a risk factor, even though 6 of 
the 8 cases of thyroid cancers appeared in patients with cGVHD(34).  
One study focused on cervical dysplasia, failing to demonstrate any association with 
genital cGVHD(35).  
From the remaining 20 studies, 11 demonstrated an association between cGVHD and 
secondary ST, with a relative risk (RR) of 1.8 - 15.374, 9 were discordant with this 
association.  
The studies that found association were unanimous in the increasing risk of oral 
carcinomas with cGVHD, namely squamous cell carcinomas (SCC). In the largest 
international study to date, Rizzo studied 28874 recipients of allo-HSCT and found 
cGVHD to be associated with an increased risk for oral and skin SCC(28). Majhail also 
reported cGVHD to be a risk factor for ST, particularly for oral carcinomas, with no 
statistically significant association with esophageal cancer (36). An international case-
control study by Curtis found that the risk for SCC increased with the cGVHD grade, 
with severe cases having 10 times increased risk (37). However, when accounting for 
the type of IS, cGVHD didn’t seem to be an independent risk factor for SCC, and  this 
is probably due to the fact that severe cases are more likely to receive drugs such as 
azathioprine, which has demonstrated to increase the risk of cancer(38,39).  
The studies that did not did association had a smaller sample size, and/or excluded 
patients who developed certain types of cancer, which might have modified the results. 
In the largest study 3372 allo-HSCT recipients were analysed, but patients with skin 
BCC and SCC were excluded (27). Other studies failed to demonstrate cGVHD as a risk 
factor for ST, even though the majority of tumors were diagnosed in sites previously 
affected by cGVHD. (6,40–45). 
• Geographical variations in epidemiology of ST 
Despite the general increase in the risk for ST with cGVHD, it is interesting to observe 
that certain types of ST are more prevalent in certain populations. This might be due to 
genetic and environmental factors or differences in cGVHD treatment.  
Within the Asian studies, Japanese studies found association between cGVHD and oral 
or esophageal cancers. Atsuta reported in a cohort of 17545 allo-HSCT recipients, that 
extensive-type cGVHD increased the risk for esophageal (RR 5.3) and oral (RR 2.9) 
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cancers; whereas limited-type cGVHD was a significant risk factor for skin cancer (RR 
5.8) (46). Yokota also demonstrated that cGVHD was an independent risk factor oral 
(RR 2.9) and esophageal (RR 4.9) SCC(47). Hasegawa found that all cases of oral and 
esophageal SCC were diagnosed in cGVHD patients(7). 
In the biggest Taiwanese study to date, Chien analyzed a cohort of 2544 allo-HSCT 
recipients and reported cGVHD as a risk factor for oral and pharynx cancers(48). 
Another Taiwanese study has shown cGVHD to be a significant risk factor for all SCC, 
with 5 of 8 oral cancer-cases diagnosed in cGVHD patients(49).  
American and European studies associate cGVHD to skin cancers. Curtis studied 
19229 allo-HSCT recipients and reported a higher risk of oral (RR 5.1) and skin (RR 
24.1) SCC in patients with cGVHD, with 9 of 14 oral SCC-cases and 7 of  8 skin SCC-
cases developing in cGVHD patients(29). In a smaller cohort, Leisenring demonstrated 
that cGVHD was a highly significant risk factor for skin, mucosal SCC, and  skin basal 
cell carcinomas(BCC) (50). 
cGVHD impact on Hematological Malignancies  
Only 2 studies focused on the risk of cGVHD for secondary hematological 
malignancies.  
One study analyzed a cohort of 26901 allo-HSCT recipients and found that both 
aGVHD and cGVHD increased the risk for late-onset PTLD (appearing more than 1 
year after transplant), with a RR of 3.17% for cGVHD(28).  
The other study focused on the risk of secondary Hodgkin’s Lymphoma (HL) in 18531 
allo-HSCT recipients. This failed to demonstrate any significant association with 
cGVHD, even though all the HL cases (n=8) had grade II-IV aGVHD and/or cGVHD 
with more than 6 months of IS(51). 
Impact of IS on secondary malignancies  
Of the 29 analyzed studies, only 9 studied the impact of the IS, used for cGVHD, on 
secondary malignancies. Two treatment-related risk factors were identified, the type of 
IS and the duration of treatment.  
As for the type of IS, the risk seems to increase in azathioprine-based regimes, although 
this might be due to an average longer duration of azathioprine-based regimes when 
compared with cyclosporine-based. The previously mentioned study by Curtis found 
that the risk for secondary malignancies was 18 times higher for regimens combining 
azathioprine, cyclosporine and steroids; this increased with addition of other drugs, 
PUVA or local field irradiation. In this same study azathioprine alone demonstrated to 
be a risk factor for skin SCC(37). In another study azathioprine alone proved to be a 
significant risk factor for the development of all-type ST (44). In a Taiwanese study 
azathioprine was as a significant risk factor for all-type ST, especially with cumulative 
doses above 15100 mg. In the same study there was a trend for an increased risk of ST 
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with sirolimus (p = 0.078) (48). According to an american study, patients treated with 
azathioprine plus cyclosporine, and to a lesser degree cyclosporine alone have an 
increased risk of late-onset PTLD(29). 
As for treatment duration, Curtis showed that besides the severity of cGVHD, long 
durations of IS, especially those with azathioprine, was an important risk factor for 
secondary SCC(35); this risk increased after 24 months of combined treatment with 
azathioprine, cyclosporine and steroids. A cohort of 19229 transplant recipients also 
found an increased frequency of secondary malignancies in patients under IS for more 
than 2 years (30). In Turkey, Gündüz found that a duration of cGVHD above 1 year was 
associated with an increased risk of epithelial tumors (3.7% vs 0.1%), mostly head and 
neck tumors (39). 
A study focusing on HPV-related cervical dysplasia reported cGVHD with 3 years IS, 
at least, as the only significant risk factor for secondary malignancies(50). However in 
another study focusing on PTLD, longer duration of IS don’t seem to be a risk 
factor(29).  
Limitations  
The following limitations may have influenced the results of this study: 
1. Review with lack of prospective studies and studies with larger sample size, 
limiting the attainment of statistical significance; 
2. The majority of included studies were designed to analyze the development of 
secondary malignancies after HSCT, and not specifically the role of cGVHD;  
3. The majority of  included studies focused one a specific type of cancer, 
potentially sub-diagnosing other malignancies;  
4. The difficulty in separating the effect of IS treatment from the isolated effect of 
cGVHD on the development of secondary malignancies.  
 
Conclusion 
Secondary malignancies are a concerning long-term complication in allo-HSCT 
recipients, with several studies reporting an increased risk. However the specific role of 
cGVHD in this setting remains unclear, with few studies delving into this issue.  
This systematic review analysis 29 studies in which the development of secondary 
malignancies after allo-HSCT and cGVHD is assessed, with 12 studies confirming 
cGVHD to be a risk factor for all-type or specific ST. The majority of ST diagnosed 
after allo-HSCT correspond to SCC of the oral cavity, skin, and in certain populations, 
the esophagus, which are organ sites frequently affected by cGVHD.  
The exact mechanisms behind the apparent association between cGVHD and secondary 
malignancies are yet to be clarified, but we speculate that the persisting tissue damage, 
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and the immune deregulation of cGVHD, contributes to the survival and proliferation of 
genetically abnormal cells. Furthermore, these patients are exposed to long periods of 
IS, which might increase the risk for tumor evolution. Results from this analysis suggest 
that the risk for ST is increased by longer durations of IS, after 24 months, and by the 
use of certain drugs such as azathioprine, with carcinogenic properties.  
It’s relatively hard to draw conclusions about the role of cGVHD in increasing the risk 
for other types of malignancies, namely hematological malignancies, thyroid and 
cervical cancers, due to the lack of studies in this setting. Such studies are much needed 
to further determinate the role of cGVHD and its treatment on secondary cancer risk.  
Given the increased risk for ST in the long-term follow-up of cGVHD patients, and the 
significant mortality related to cancer, it might be beneficial to implement specific long-
term cancer screening routines in these patients, especially for skin, oral and in some 
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Table 1 : Characteristics and results of included studies. 
Reference Study type; 
Dimension; 
Location. 
Age at HSCT; 






























> 14-57 years 
(m: 39);  
> 100% allo.  
> 91.4% BM, 







> n = 20; 
> 18 ST, 2 NHL; 




No association (p not 







> n = 133; 
> France. 
> NS; 
> 100% allo.  
> 100% BM;  
> 49.6%; 
> NS. 
> n = 11; 
> 11 ST; 
> NS. 







& al., 2014) 
> Retrospective 
cohort;  
> n = 17545; 
> Japan. 
> 16-85 years 
(m: 40);  
> 100% allo; 
> 68% BM, 
20% PB, 12% 
CB.  
 
> 41.2% at 2 
years; 
> NS.   
> n = 269; 





cGVHD and ST (RR 
1.8); oral  (RR 2.9) and 
esophageal (RR 5.3) 
cancers.  
Significant association 
between L-cGVHD and 









> n = 615; 
> China. 
> 18-65 years 
(m: 35.5); 
> 100% allo; 
> NS.  
> 27%; 
> NS. 
> n = 18 
> 9 ST, 5 PTLD, 
4 MDS/AML;  
> NS. 
 




(Baker K. , 
DeFor, 




> n = 3372; 
> USA. 
> 1-67 years (m: 
24); 
> 42% allo, 
35% auto; 
> 100% BM; 
> NS; 
> NS. 
> n = 147; 











& al., 1996) 
> Retrospective 
cohort; 
> n = 2150; 
> USA. 
> 1-67 years (m: 
20); 
> 65% allo, 
35% auto; 
> 100% BM; 
 
> NS; 
> NS.  
> n = 54; 
> 22 PTLD, 17 
ST, 11 
MDS/AML, 2 
NHL, 1 HL;  
> NS; 
 
No association with SM or 









> n = 49;  
> USA. 
> 17-66 years 
(m: 55); 
> 100% allo.  
> NS 
 
> 47.2% (E); 
> NS.  
> n = 18;  
> 18 skin 
cancers. 
> 0.17-2.17 years 
(m: 1); 
 
No association with skin 





& al., 2011) 
> Retrospective 
cohort; 
> n = 170; 
> Taiwan.  
> 15-60 years 
(m: 31); 
> 100% allo; 
> 80.6% BM, 




8.8% E);  
> 24.7% 
treated for 
more than 1 
year with Aza 
and steroids.  
 
> n = 8; 
> 8 ST.  












> n = 2544; 
> Taiwan 
> 20-45 years 
(m: 32); 
> 59.5% allo, 
40.5% auto; 









among others.  
 
> n = 43; 
> 43 ST; 
> NS; 
Significant association 
with head and neck 
cancers (RR 2.84; p = 
0.046). Azathioprine 
increases significantly risk 
of SM (RR 2.55; p = 
0.025), especially 
cumulative doses above 
15,100 mg (RR 3.58; p = 
0.01).  
  







> n = 68936; 
> EU. 
(m: 11.2 – only 
considering the 
SM cases); 
> 49% auto, 
42% allo; 
> NS;  
 
> NS; > 32 thyroid 
cancers; 
> NS (m: 6.2).   
with thyroid cancer (RR 
2.94; p = 0.017). 
(Cohen, 
Rovelli, Van 




> n = 113;  
> Italy. 
> 1.7-18 years 
(m: 10); 
> 100% allo; 
> NS; 
> 60% (43% 
L, 17% E).  
> NS; 
> n = 8 
> 8 thyroid 
cancers; 
> 3.1-15.7 years 
(m: 8.5). 
 
No association with 




Rizzo, & al., 
2005) 
> Case-control; 
> n = 24011; 
> International. 
> 3.5-61.3 years 
(m: 26.5);  
> 100% allo; 
> NS;  
> 72.4% in 
case-patients, 







+ Aza + 
Steroids + 
other (21.4%), 















> n = 183; 
> 183 ST; 
> 0.9-22.9 years 
(m: 7);  
  
Significant association 
with SCC, when not 
considering the type of 
drug therapy or duration 
of treatment (RR 2.79; p = 
0.01); subsequent models 
found a highly significant 
SCC risk for cGVHD IS 
treatment ≥ 24 months 
(RR 8.44) – in this model 
cGVHD was not found a 
significant independent 
risk factor for SCC. When 
looking at the type and 
duration of cGVHD 
treatment, the risk was 
highly significant for 
combined treatments with 
Aza, CsA and steroids 
(RR 18.61), especially for 
≥ 12 months (38.71); and 
significant for Aza and 
steroids (RR 2.77; p = 
0.07), especially for ≥ 24 
months (RR 5.14; p = 
0.09). When looking at 













risk was highly significant 
in severe disease (RR 
9.93) and significant in 
moderate disease (RR 
2.73; p = 0.08). cGVHD 
was most strongly 
associated with skin SCC 









> n = 19229; 
> USA. 
> NS (m :25.5);  
> 97.2% allo, 
2.8% syn; 
> 100% BM;  
 
> 17%;  
> NS. 
> n = 80;  
> 80 ST; 
> NS; 
Significant association 
with skin SCC (RR 24.1; 
p < 0.001) and oral SCC 









> n = 212;  
> USA. 
> 1-42 years 
(m:18); 







among others.  
 
> n = 11; 
> 11 ST; 
> NS. 
No association with SM (p 
not statistical significant).   






> n = 700; 
> International. 
> 1.8-67 years 
(m: 18); 
> 100% allo; 
> 100% BM.  
> 31%; 
> NS. 
> n = 23;  
> 18 ST, 3 
PTLD, 2 ALL; 
> NS (m: 7.58 
for all cancers; 
m: 8.25 for solid 
tumors). 
Significant association 
with SM in the 
univariate analysis (RR 
3.7; p = 0.0099).  In 
multivariate analysis 
treatments with Aza 
increased significantly the 







> n = 926; 
> Canada. 
> 12-65 years 
(m: 39); 
> 100% allo; 
> 87% BM, 





> n = 30; 
> 30 ST; 
> NS (m: 6.8). 
No association with SM (p 










> n = 15; 
> 12 ST, 3 
Significant association 
between cGVHD ≥ 1 
29 
 
& al., 2017) > n = 979; 
> Turkey. 
> 100% allo; 
> 70% PB, 27% 
BM, 2% CB.  
PTLD; 
> 0.25-1.67 years 
(0.75) for PTLD; 
0.5-26.33 years 
(m: 7.75) for ST.  
 
year and SM (RR 7.1; p 
= 0.001); these patients 
also had more epithelial 
cancer risk than ones with 
shorter disease duration 









> n = 809; 
> Japan. 
> 15-70 years 
(m: 34); 
> 73.1% allo, 







> NS.  
> n = 19; 
> 19 ST; 
> 1-11.58 years. 
 
Significant association 
between E-cGVHD  and 








> n = 26901; 
> USA. 
> 0.1-68 years 
(m: 26.6); 
> 100% allo; 
> NS.  
> 17%; 
> NS.  
> n = 127;  
> 127 PTLD; 
> NS (83% 
developed within 
1 year).  
Significant association 
with late-onset PTLD 
(RR 3.17; 95% CI = 1.45-
8.30) CsA (RR 3.18; 95% 
CI = 1.25-8.06) or CsA + 
Aza (RR 7.81; 95% CI = 
1.18-51.94) increased risk 








> n = 4810; 
> USA. 
> 0.3-72.6 years 
(m: 31.3); 
> 100% allo; 
> NS. 
> NS; 
> NS.  
> n = 253;  
> 253 ST; 
> NS (m: 7.9 for 




with SCC (RR 3.0) and  
skin BCC (RR 1.6; p = 









> n = 56;  
> Canada  
 
> NS; 
> 100% allo; 
> 100% BM. 
> NS; 
> NS. 
> n = 3;  
> 3 ST; 
> NS.  
 
No association with SM (p 








> n = 4318; 
> International 
> 1-60 years (m: 
29) in AML 
patients; 1-60 
years (m: 36) in 
> 32% (30-
35%) at 3 
years for AML 
patients; 46% 
> n = 66; 
> 66 ST; 
> NS (m: 6).  
 
Significant association 
with ST (RR 2.4; p = 
0.001); and oral cancer 




> 100% allo; 
> 84% BM, 
16% PB.  
(44-48%) at 3 
years for CML 
patients; 











> n = 28874; 
> International 
> 0.08-72.41 
years (m: 27); 
> 100% allo; 
> 100% BM. 
> 31% at 3 
years; 
> NS. 
> n = 189;  
> 189 ST; 
> NS. 
Significant association 
with skin and oral SCC 
(RR 5.04; 95% CI = 2.90-
9.00). The risk associated 
with cGVHD decreased in 
patients with acute 











> n = 18531; 
> USA 
> 1-72 years (m: 
26); 
> 100% allo; 
> NS.  
> 30% (E); 
> NS. 
> n = 8; 
> 8 HL; 
> 2.9-9.1 years 
(m: 4.2). 
E-cGVHD was not found 
a statistically significant 








> n = 38; 
> USA 
> 9-60 years (m: 
30); 
> 76% allo; 
> 24% PB.  
> 97%; 
> 17% adult 
females did 
more than 3 
months of IS. 
> n = 15;  
> 12 SIL (HPV 
+), 3 ASCUS 
(HPV-);  
> NS (m: 4.25).  
Significant association 
between cGVHD 
requiring prolonged IS 
(≥ 3 years) and HPV-
related cervical 









> n = 557; 
> Canada 
> 24.2-47.4 
years (m: 35.8) 
for patients who 
developed a 
SM. 23-42.2 
years (m: 32.6) 
for patients who 
did not; 
> 100% allo; 
> 100% BM.  
 
> NS; 
> NS.  
> n = 31; 
> 27 ST, 4 
hematological 
malignancies; 
> NS (m: 6.79).  
No association with SM (p 
not statistical significant).  







> n = 3273; 
> Australia 
years (m: 40.4); 
> 100% allo; 
> 53.5% PB, 
40.9% BM, 
1.3% CB. 
> NS.  > 76 ST.  
> 0.13-13.5 years 
(m: 3.54).  
with SM (HR 1.65; p = 
0.008) - cGVHD patients 
presenting a higher 
incidence of SM (SIR 









> n = 2062; 
> Japan 
> 7-68 years (m: 
36); 
> 100% allo; 
> 75.5% BM, 




> n = 30; 
> 30 ST; 
> NS (m: 5.6).  
Significant association 
with ST (RR 2.4; p = 
0.043); and oral and 
esophageal SCC (RR 4.9; 
p = 0.019). 
Abreviations: SC: stem-cell; allo, allogeneic-hematopoietic stem cell transplant; BM, bone marrow; 
PB, peripheral blood; NS, not stated; SM, secondary malignancy; ST, solid tumor; NHL, non-
Hodgkin lymphoma; SM, secondary malignancy; CB, cord blood; E, extensive type; L, limited-
type; HL, Hodgkin lymphoma; CsA, ciclosporine; ATG, anti-thymocyte globulin; auto, autologous-
hematopoietic stem cell transplant; SCC, squamous cell carcinoma; Aza, azathioprine; IS, 
imunossupresive; syn, syngeneic; ALL, acute lymphoblastic leucemia; BCC, basocelular 
carcinoma; CML, chronic myeloid leucemia; SIL, squamous intraepithelial lesion; ASCUS, 
atypical squamous cells of undetermined significance; m, median; SIR, standardized indice ratio.  
 
 
